NCT04860947View on ClinicalTrials.gov

Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients

Active, not recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Multiple Sclerosis

Interventions

DIAGNOSTIC_TEST

Brain MRI

"* Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection."

DIAGNOSTIC_TEST

Spinal Cord MRI

Sagittal T2 Sagittal T1 with Gadolinium injection

DIAGNOSTIC_TEST

Retinal imaging

spectral-domain high definition optical coherence tomography

Trial Locations (1)

30029

CHU de Nimes, Nîmes

All Listed Sponsors

collaborator

Institut de Recherches en Biothérapie

UNKNOWN

lead

Centre Hospitalier Universitaire de Nīmes

OTHER